GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies.
about
GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
GCG100649, A Novel Cyclooxygen ...... inical Development Strategies.
@en
GCG100649, A Novel Cyclooxygen ...... inical Development Strategies.
@nl
type
label
GCG100649, A Novel Cyclooxygen ...... inical Development Strategies.
@en
GCG100649, A Novel Cyclooxygen ...... inical Development Strategies.
@nl
prefLabel
GCG100649, A Novel Cyclooxygen ...... inical Development Strategies.
@en
GCG100649, A Novel Cyclooxygen ...... inical Development Strategies.
@nl
P2093
P2860
P356
P1476
GCG100649, A Novel Cyclooxygen ...... inical Development Strategies.
@en
P2093
Garret A FitzGerald
Jeffrey S Barrett
Naji Alamuddin
Sarapee Hirankarn
P2860
P304
P356
10.1002/CPDD.47
P577
2013-07-25T00:00:00Z